secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alkermes plc. (ALKS)
CIK:        0001520262
Form:       8-K
Filed at:   2025-09-12T23:59:59+00:00
Accession:  0001193125-25-201840
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alkermes appoints Joshua Reed as CFO effective September 15, 2025
-----------------------------------------------------------------

- Reed will report to CEO Richard Pops and join the management committee.
- He brings 30+ years finance experience; most recently CFO of Omega Therapeutics and Aldeyra Therapeutics, and earlier at Bristol Myers Squibb.
- Base salary $615,000, target annual cash bonus 50% of base, new-hire equity grant valued at $3.5 million.
- Blair C. Jackson, EVP/COO, had been serving as interim principal financial officer; Samuel Parisi remains interim principal accounting officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1520262/000119312525201840/0001193125-25-201840-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1520262/000119312525201840/alks-20250912.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-201840

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer